Rubius Therapeutics Alpha and Beta Analysis
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rubius Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rubius Therapeutics over a specified time horizon. Remember, high Rubius Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rubius Therapeutics' market risk premium analysis include:
Beta 0.0 | Alpha 0.0 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rubius |
Rubius Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rubius Therapeutics market risk premium is the additional return an investor will receive from holding Rubius Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rubius Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rubius Therapeutics' performance over market.| α | 0.00 | β | 0.00 |
Rubius Therapeutics Fundamentals Vs Peers
Comparing Rubius Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rubius Therapeutics' direct or indirect competition across all of the common fundamentals between Rubius Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rubius Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Rubius Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Rubius Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rubius Therapeutics to competition |
| Fundamentals | Rubius Therapeutics | Peer Average |
| Return On Equity | -1.85 | -0.31 |
| Return On Asset | -0.47 | -0.14 |
| Current Valuation | 22.18 M | 16.62 B |
| Shares Outstanding | 90.4 M | 571.82 M |
| Shares Owned By Insiders | 5.55 % | 10.09 % |
| Shares Owned By Institutions | 72.61 % | 39.21 % |
| Number Of Shares Shorted | 1.53 M | 4.71 M |
Rubius Therapeutics Opportunities
Rubius Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Rubius Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rubius or other pink sheets. Alpha measures the amount that position in Rubius Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Rubius Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Rubius Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rubius Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rubius Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rubius Therapeutics. Please utilize our Beneish M Score to check the likelihood of Rubius Therapeutics' management manipulating its earnings.
| 10th of March 2023 Upcoming Quarterly Report | View | |
| 9th of May 2023 Next Financial Report | View | |
| 31st of December 2022 Next Fiscal Quarter End | View | |
| 10th of March 2023 Next Fiscal Year End | View | |
| 30th of September 2022 Last Quarter Report | View | |
| 31st of December 2021 Last Financial Announcement | View |
Build Portfolio with Rubius Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |